Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 54508
Gene Symbol: EPB41L4A-DT
EPB41L4A-DT
0.010 Biomarker disease BEFREE Therefore, our purpose was to investigate the possible regulatory role of the lncRNA EPB41L4A-AS2 in the progression of OC. 31645082 2020
Entrez Id: 64115
Gene Symbol: VSIR
VSIR
0.010 AlteredExpression disease BEFREE Moreover, VISTA expression in TCs, but not in ICs, was associated with prolonged progression-free and overall survival in patients with high-grade serous ovarian cancer. 31781843 2020
Entrez Id: 794
Gene Symbol: CALB2
CALB2
0.010 Biomarker disease BEFREE CRT is expressed in ovarian cancer tissues in up to 40% of cases; however, its clinical relevance as blood-based biomarker for ovarian cancer is unknown. sCRT was determined by calretinin enzyme-linked immunoabsorbent assay (Calretinin-ELISA, DLD Diagnostika GmbH, Hamburg, Germany) in a total of 515 serum samples from 116 healthy controls and 134 ovarian cancer patients (thereof 86% with Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] III/IV), including samples at primary diagnosis and at four longitudinal follow-up time points in the course of treatment and at recurrence. sCRT level was significantly increased in ovarian cancer patients compared to healthy controls (estimated difference = 0.3 ng/ml, p < 0.001), was mostly independent from CA125 (r ≤ 0.388) and enabled accurate discrimination between cases and controls (area under the curve = 0.85). 31509615 2020
Entrez Id: 201853
Gene Symbol: LINC00504
LINC00504
0.010 AlteredExpression disease BEFREE LINC00504 was upregulated in OC cell lines and specimens. 31691157 2020
Entrez Id: 1356
Gene Symbol: CP
CP
0.010 Biomarker disease BEFREE Delivery of si-LINC00176, oe-LINC00176, si-BCL3 and si-CP plasmids was conducted to explore the effects of LINC00176 on ovarian cancer. 31668012 2020
Entrez Id: 406994
Gene Symbol: MIR212
MIR212
0.010 Biomarker disease BEFREE Long non-coding RNA KCNQ1OT1 accelerates the progression of ovarian cancer via microRNA-212-3/ LCN2 axis. 31653278 2020
Entrez Id: 404201
Gene Symbol: WDFY3-AS2
WDFY3-AS2
0.010 Biomarker disease BEFREE According to bioinformatics analysis, WDFY3-AS2 was speculated to affect OC by sponging miR-18a and modulating RORA. 31347170 2020
Entrez Id: 64221
Gene Symbol: ROBO3
ROBO3
0.010 AlteredExpression disease BEFREE High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. 31800094 2020
Entrez Id: 64344
Gene Symbol: HIF3A
HIF3A
0.010 AlteredExpression disease BEFREE Thus, upregulated HIF3A expression accelerates the progression of OC. 31595977 2020
Entrez Id: 101927597
Gene Symbol: NCK1-DT
NCK1-DT
0.010 AlteredExpression disease BEFREE As for mechanistic investigation, starBase (http://starbase.sysu.edu.cn/) suggested that NCK1-AS1 expression in OC tissues was significantly positively correlated with its adjacent gene, NCK adaptor protein 1 (NCK1). 31761329 2020
Entrez Id: 10984
Gene Symbol: KCNQ1OT1
KCNQ1OT1
0.010 Biomarker disease BEFREE Here, we aimed to explore the effect of KCNQ1OT1 on the carcinogenesis of ovarian cancer, as well as to investigate miR-212-3p roles in this process. 31653278 2020
Entrez Id: 57560
Gene Symbol: IFT80
IFT80
0.010 AlteredExpression disease BEFREE Collectively, the data from the present study demonstrated that the ATD2 gene was frequently amplified and protein expression levels were upregulated in OC. 31746426 2020
Entrez Id: 811
Gene Symbol: CALR
CALR
0.010 Biomarker disease BEFREE CRT is expressed in ovarian cancer tissues in up to 40% of cases; however, its clinical relevance as blood-based biomarker for ovarian cancer is unknown. sCRT was determined by calretinin enzyme-linked immunoabsorbent assay (Calretinin-ELISA, DLD Diagnostika GmbH, Hamburg, Germany) in a total of 515 serum samples from 116 healthy controls and 134 ovarian cancer patients (thereof 86% with Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] III/IV), including samples at primary diagnosis and at four longitudinal follow-up time points in the course of treatment and at recurrence. sCRT level was significantly increased in ovarian cancer patients compared to healthy controls (estimated difference = 0.3 ng/ml, p < 0.001), was mostly independent from CA125 (r ≤ 0.388) and enabled accurate discrimination between cases and controls (area under the curve = 0.85). 31509615 2020
Entrez Id: 7347
Gene Symbol: UCHL3
UCHL3
0.010 Biomarker disease BEFREE UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway. 31477831 2020
Entrez Id: 254099
Gene Symbol: LINC01342
LINC01342
0.010 AlteredExpression disease BEFREE In this study, LINC01342 was upregulated in OC tissue in the GSE38666 microarray and in tumor tissue samples collected in our center. 31595977 2020
Entrez Id: 6535
Gene Symbol: SLC6A8
SLC6A8
0.010 Biomarker disease BEFREE CRT is expressed in ovarian cancer tissues in up to 40% of cases; however, its clinical relevance as blood-based biomarker for ovarian cancer is unknown. sCRT was determined by calretinin enzyme-linked immunoabsorbent assay (Calretinin-ELISA, DLD Diagnostika GmbH, Hamburg, Germany) in a total of 515 serum samples from 116 healthy controls and 134 ovarian cancer patients (thereof 86% with Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] III/IV), including samples at primary diagnosis and at four longitudinal follow-up time points in the course of treatment and at recurrence. sCRT level was significantly increased in ovarian cancer patients compared to healthy controls (estimated difference = 0.3 ng/ml, p < 0.001), was mostly independent from CA125 (r ≤ 0.388) and enabled accurate discrimination between cases and controls (area under the curve = 0.85). 31509615 2020
Entrez Id: 53827
Gene Symbol: FXYD5
FXYD5
0.010 Biomarker disease BEFREE A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. 31746425 2020
Entrez Id: 400629
Gene Symbol: TEX19
TEX19
0.010 AlteredExpression disease BEFREE TEX19 was significantly upregulated in OC which correlated to higher TNM stage, lymph node involvement, and invasiveness. 31843525 2020
Entrez Id: 7186
Gene Symbol: TRAF2
TRAF2
0.010 Biomarker disease BEFREE UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway. 31477831 2020
Entrez Id: 5920
Gene Symbol: PLAAT4
PLAAT4
0.010 Biomarker disease BEFREE Survival analyses disclosed RIG-I as an independent marker of poor outcome in OC. 31800094 2020
Entrez Id: 23586
Gene Symbol: DDX58
DDX58
0.010 AlteredExpression disease BEFREE High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. 31800094 2020
Entrez Id: 284739
Gene Symbol: C20orf204
C20orf204
0.010 Biomarker disease BEFREE Delivery of si-LINC00176, oe-LINC00176, si-BCL3 and si-CP plasmids was conducted to explore the effects of LINC00176 on ovarian cancer. 31668012 2020
Entrez Id: 9358
Gene Symbol: ITGBL1
ITGBL1
0.010 AlteredExpression disease BEFREE We noticed that ITGBL1 expression was significantly upregulated in ovarian cancer tissues compared to that in adjacent non-cancer tissues and high expression of ITGBL1 was significantly associated with lymph node invasion and advanced FIGO stage. 31683459 2020
Entrez Id: 29123
Gene Symbol: ANKRD11
ANKRD11
0.010 GeneticVariation disease BEFREE Two new putative OC risk genes were identified, namely, ANKRD11, a putative tumor suppressor, and POLE, an enzyme involved in DNA repair and replication. 31265121 2020
Entrez Id: 126014
Gene Symbol: OSCAR
OSCAR
0.010 Biomarker disease BEFREE The OSCAR (NCT01863693) study assessed the impact of front-line bevacizumab-containing therapy on safety and oncologic outcomes in patients with advanced ovarian cancer in the UK. 31780570 2020